Bristol Myers Squibb Company $BMY Shares Sold by Capital International Inc. CA

Capital International Inc. CA lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 39.4% during the 4th quarter, HoldingsChannel reports. The firm owned 210,148 shares of the biopharmaceutical company’s stock after selling 136,715 shares during the quarter. Capital International Inc. CA’s holdings in Bristol Myers Squibb were worth $11,335,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Tacita Capital Inc boosted its position in Bristol Myers Squibb by 31.0% in the 4th quarter. Tacita Capital Inc now owns 1,305 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 309 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in Bristol Myers Squibb by 34.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 4,315,403 shares of the biopharmaceutical company’s stock worth $232,773,000 after purchasing an additional 1,097,684 shares in the last quarter. Tradition Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $249,000. Dearborn Partners LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $203,000. Finally, MCF Advisors LLC boosted its position in Bristol Myers Squibb by 112.4% in the 4th quarter. MCF Advisors LLC now owns 15,886 shares of the biopharmaceutical company’s stock worth $857,000 after purchasing an additional 8,406 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Barclays began coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective on the stock. Guggenheim reiterated a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Bank of America decreased their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $61.31.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

Bristol Myers Squibb Stock Down 0.1%

NYSE BMY opened at $57.24 on Monday. The business has a fifty day moving average price of $58.10 and a 200 day moving average price of $56.59. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a market cap of $116.88 billion, a P/E ratio of 16.08, a P/E/G ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the prior year, the company earned $1.80 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.